Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Follicular lymphoma: MRD response correlates with outcomes

Pott C et al. ASH 2018, Abstract 396.

Key clinical point: MRD response assessments have prognostic value in previously untreated follicular lymphoma patients receiving immunochemotherapy.

Major finding: Progression-free survival (PFS) probability was about 80% in patients who were MRD negative at the end of induction, compared with about 50% in patients who were MRD positive (hazard ratio, 0.38).

Study details: An analysis of data from 634 patients in the phase 3 GALLIUM study.

Disclosures: The GALLIUM study is supported by F. Hoffmann–La Roche. Dr. Pott reported having no financial disclosures.

Read the article.


Pott C et al. ASH 2018, Abstract 396.